| Nasrollah Eslami, MD | |
|
1004 1st St N, Ste 330, Alabaster, AL 35007-8766 | |
| (205) 664-2967 | |
| (205) 664-9689 |
| Full Name | Nasrollah Eslami |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 54 Years |
| Location | 1004 1st St N, Alabaster, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235147232 | NPI | - | NPPES |
| 130024556 | Other | AL | RAILROAD MEDICARE |
| 009943185 | Medicaid | AL | |
| 51519562ESL | Other | AL | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 9098 (Alabama) | Primary |
| Entity Name | Neurology Neurodiagnostic Lab Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417165127 PECOS PAC ID: 8022905413 Enrollment ID: O20040301001063 |
News Archive
Optical coherence tomography (OCT) provides safe and improved guidance for patients undergoing percutaneous coronary intervention to treat coronary artery disease, according to results from the ILLUMIEN III: OPTIMIZE PCI trial.
One of the first studies to examine the effect of climate change on diseases such as influenza that are transmitted directly from person to person has found that higher temperatures and increased rainfall could make outbreaks less severe but more common, particularly in North America.
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Boston Medical Center's StreetCred program has been named to the second cohort of the Aspen Family Prosperity Innovation Community, an Aspen Institute initiative for breakthrough innovations and collaborations that position families to reach educational success, economic prosperity, and health and well-being.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nasrollah Eslami, MD 1004 1st St North, Ste 330, Alabaster, AL 35007 Ph: (205) 664-2967 | Nasrollah Eslami, MD 1004 1st St N, Ste 330, Alabaster, AL 35007-8766 Ph: (205) 664-2967 |
News Archive
Optical coherence tomography (OCT) provides safe and improved guidance for patients undergoing percutaneous coronary intervention to treat coronary artery disease, according to results from the ILLUMIEN III: OPTIMIZE PCI trial.
One of the first studies to examine the effect of climate change on diseases such as influenza that are transmitted directly from person to person has found that higher temperatures and increased rainfall could make outbreaks less severe but more common, particularly in North America.
Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).
Boston Medical Center's StreetCred program has been named to the second cohort of the Aspen Family Prosperity Innovation Community, an Aspen Institute initiative for breakthrough innovations and collaborations that position families to reach educational success, economic prosperity, and health and well-being.
› Verified 6 days ago
Sunil Kumar Goli, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1004 1st St N, Suite 350, Alabaster, AL 35007 Phone: 205-664-7852 Fax: 205-664-7822 | |
David Baker O'neal, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1004 1st St N Ste 150, Alabaster, AL 35007 Phone: 205-620-8723 Fax: 205-620-8724 |